Invivo anti-mouse PD-1 Recombinant mAb
Invivo anti-mouse PD-1 Recombinant mAb
Product Details
Product Details
Product Specification
| Synonyms | Programmed cell death protein 1; Protein PD-1; mPD-1; CD279; Pd1; Pdcd1 |
| Location | Cell membrane |
| Accession | Q02242 |
| Clone Number | 29F.1A12 |
| Antibody Type | Rat mAb |
| Isotype | Rat IgG2a, κ |
| Isotype Control | Invivo rat IgG2a isotype control, anti-trinitrophenol |
| Application | In vivo blocking of PD-1/PD-L signaling |
| Reactivity | Ms |
| Purification | Protein G |
| Concentration | 5 mg/ml |
| Purity | >95% (Determined by SDS-PAGE) |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage |
2 to 8 °C for 2 weeks under sterile conditions; -20 °C for 3 months under sterile conditions; -80 °C for 24 months under sterile conditions. Please avoid repeated freeze-thaw cycles. |
Background
This antibody recognizes the same epitope as clone 29F.1A12. Programmed cell death protein 1 (PD-1), also known as CD279, is a type I transmembrane protein and a member of the CD28 immunoglobulin superfamily. It is primarily expressed on the surface of various immune cells, including T cells, B cells, macrophages, dendritic cells, and natural killer cells. PD-1 plays a crucial role in regulating immune responses by binding to its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed on antigen-presenting cells and tumor cells. When PD-1 interacts with its ligands, it triggers inhibitory signals that downregulate T cell activity, preventing excessive immune responses and promoting self-tolerance. However, this pathway can also be exploited by cancer cells to evade immune surveillance, leading to tumor progression. As a result, PD-1 has become a key target in cancer immunotherapy, with several anti-PD-1 antibodies approved for treating various cancers, achieving significant and durable efficacy in some patients.
